Rituximab is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of B-cell non-Hodgkin lymphoma. It is also approved to be used with methotrexate to treat rheumatoid arthritis. Rituximab is also being studied in the treatment of other types of cancer and other conditions.
Antibodies are the foot soldiers of our immune system. These specialized, Y-shaped proteins attach to bacteria and viruses, where they either block the pathogen's activity directly, or signal the immune system's cells to destroy the invader.
Macrophages are a type of white blood cell that can engulf and destroy cancer cells. A research group led by Professor MATOZAKI Takashi, Associate Professor MURATA Yoji, and YANAGITA Tadahiko, discovered that by using an antibody for a particular protein found on macrophages, the macrophage is activated, and cancer cells are effectively eliminated.
The multiple sclerosis (MS) therapy alemtuzumab can trigger severe, unpredictable side effects.
A new review by the International Osteoporosis Foundation Chronic Inflammation and Bone Structure Working Group concludes that early and aggressive treatment of Rheumatoid Arthritis (RA) with biologic drugs, specifically biological disease-modifying anti-rheumatic drugs (DMARDs), may be most effective in halting progressive bone loss in patients with RA.
Chronic fatigue syndrome (CFS), sometimes referred to as myalgic encephalomyelitis (ME), a mysterious, debilitating and misunderstood disease that affects an estimated 1 million Americans, will be the focus of an international conference on October 27-30, 2016.
Although diffuse large B-cell lymphoma (DLBCL) is a curable disease in most patients aged 65 years or older, these patients are also at higher risk of chemotherapy-related death within the first 30 days of treatment.
Primary cutaneous lymphomas, cancers of the lymphatic system, occur in the skin and originate either from T-lymphocytes (T-cell lymphomas, incidence 75%) or in B-cell lymphocytes (B-cell lymphomas, 25%).
Determining whether breast cancer has spread to sentinel lymph nodes (SLN) is key to prognosis and treatment, making SLN mapping critical.
Würzburg neurologists have discovered an antibody that is involved in triggering certain forms of neuropathies. This discovery also allowed them to show a way to treat these diseases successfully.
The American Autoimmune Related Diseases Association, Inc. is spotlighting two new research studies originally reported in ScienceDaily.
Already in 2014, the German Institute for Quality and Efficiency in Health Care examined in an early benefit assessment whether idelalisib offers advantages over the appropriate comparator therapy for patients with chronic lymphocytic leukaemia (CLL).
In a study with potentially major implications for the future treatment of autoimmunity and related conditions, scientists from the Perelman School of Medicine at the University of Pennsylvania have found a way to remove the subset of antibody-making cells that cause an autoimmune disease, without harming the rest of the immune system.
The targeted therapy everolimus may be safely combined with R-CHOP for new, untreated diffuse large B-cell lymphoma according to the results of a pilot study by Mayo Clinic researchers published in the Lancet Haematology.
Rituximab may be an attractive treatment option for patients with relapsing-remitting multiple sclerosis, suggest phase II study findings showing its efficacy in controlling inflammatory activity.
Rebound syndrome following cessation of fingolimod for multiple sclerosis occurs at a clinically relevant rate, shows research, prompting the need for further study on how best to sequence and discontinue such drugs.
Rituximab is more effective and better tolerated than fingolimod for patients with multiple sclerosis needing to switch from natalizumab due to JC-virus antibody positivity, research suggests.
A new study indicates that rituximab is more effective than fingolimod for preventing relapses in patients with highly active multiple sclerosis switching from treatment with natalizumab.
Rituximab is an effective and well-tolerated second-line treatment for patients with autoimmune limbic encephalitis, suggests research.
AbbVie, a global biopharmaceutical company, today announced the European Medicines Agency has granted Orphan Drug Designation to venetoclax, an investigational, oral B-cell lymphoma-2 (BCL-2) inhibitor, for the treatment of acute myeloid leukemia (AML).
Positive findings from two clinical trials have been published for the immunomodulatory agent lenalidomide in patients with heavily pretreated mantle cell lymphoma, and in adults with T-cell leukaemia-lymphoma or peripheral T-cell lymphoma.